Vimarsana
Biggest News Aggregation in the World

Page 3 - Mark Joinnides News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Joinnides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Joinnides Today - Breaking & Trending Today

Vaxxinity to Present at Upcoming Investor Conferences in September - Vimarsana News

Vaxxinity to Present at Upcoming Investor Conferences in September

CAPE CANAVERAL, Fla., Aug. 29, 2023 -- Vaxxinity, Inc. ; class='js-l-obf link link--blue'

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical ... - Vimarsana News

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical ...

Phase 2a data published in The Lancet’s eBioMedicinesupports further development of UB-311

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Aug. 09, 2023 -- Vaxxinity, Inc. ; class='js-l-obf link link--blue'

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice - Vimarsana News

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients - Vimarsana News

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients

Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...